Eli Lilly gives $20M upfront cash injection to Elektrofi in next-gen subcutaneous drug collab

24 Oct 2023
·
Deals
www.fiercebiotech.com
License out/inPROTACs
Eli Lilly gives $20M upfront cash injection to Elektrofi in next-gen subcutaneous drug collab
Preview
Source: FierceBiotech
Elektrofi’s tech is used to engineer ultra-high concentration formulations of protein-based meds that can be administered as quick, small skin injections.
Eli Lilly has tapped up drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could produce the next generation of subcutaneously administered therapies.
In return for $20 million upfront, Lilly will secure exclusive rights to three undisclosed targets, for which the Big Pharma will then take on responsibility for clinical development and hopefully commercialization.
Should any of the resulting candidates make it that far, Elektrofi could be in line for over $150 million in milestone payments per target, plus a slice of the royalties. Lilly also has the option to expand the agreement to encompass an extra two targets in return for further payments.
Elektrofi’s technology is used to engineer ultra-high concentration, low-viscosity protein formulations that can be administered as low-volume, subcutaneous injections. The formulations can even be administered using commercially available devices like autoinjectors, which could one day transform IV drugs into products easy to use at home.
The Boston-based company said the Lilly deal “strengthens [our] position as a global partner and scientific technology innovator that is reformulating the future of biologic delivery.”
“Our collaboration with Lilly further validates the potential value of our expertise, our capabilities, and our proprietary technology platform, especially in the areas of autoimmune disease, oncology and neuroscience,” Elektrofi CEO Chase Coffman said in the release. “Our team is looking forward to collaborating with Lilly and leveraging the talents and insights of the collective team to accomplish what is yet to be done.”
Lilly isn’t the first Big Pharma to show an interest. Back in 2020, Takeda established a pact to see if Elektrofi’s tech could be used to enable simpler dosing of the Japanese pharma’s plasma-derived therapies. The biotech followed it up with a deal with argenx the following year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.